{"filing":{"accession_number":"0001213900-26-061021","cik":"0001874252","ticker":"QUCY","company_name":"Quantum Cyber N.V.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"ea0292112-8k_quantum.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1874252/000121390026061021/ea0292112-8k_quantum.htm"},"events":[{"id":9062,"run_id":7957,"accession_number":"0001213900-26-061021","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"This Item 8.01 disclosure describes a comprehensive business overview and strategic pivot for Quantum Cyber N.V., including a name change from \"Mainz Biomed N.V.\" to \"Quantum Cyber N.V.\" in April 2026 and formation of a U.S. subsidiary (Quantum Drones Corporation) in May 2026. The filing details a fundamental shift from a pharmaceutical genomics company to an AI and quantum computing-focused autonomous vehicle platform developer. While the prose does not fit neatly into the specific event categories (no M\u0026A completion, no earnings release, no executive change, no covenant breach), the material business transformation and strategic repositioning would affect a reasonable investor's assessment of the registrant's operations, market focus, and risk profile.","company_name":"Quantum Cyber N.V.","ticker":"QUCY","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1549,"accession_number":"0001213900-26-061021","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"This Item 8.01 disclosure describes a comprehensive business overview and strategic pivot for Quantum Cyber N.V., including a name change from \"Mainz Biomed N.V.\" to \"Quantum Cyber N.V.\" in April 2026 and formation of a U.S. subsidiary (Quantum Drones Corporation) in May 2026. The filing details a fundamental shift from a pharmaceutical genomics company to an AI and quantum computing-focused autonomous vehicle platform developer. While the prose does not fit neatly into the specific event categories (no M\u0026A completion, no earnings release, no executive change, no covenant breach), the material business transformation and strategic repositioning would affect a reasonable investor's assessment of the registrant's operations, market focus, and risk profile.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:14:01.547182+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1549,"accession_number":"0001213900-26-061021","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"This Item 8.01 disclosure describes a comprehensive business overview and strategic pivot for Quantum Cyber N.V., including a name change from \"Mainz Biomed N.V.\" to \"Quantum Cyber N.V.\" in April 2026 and formation of a U.S. subsidiary (Quantum Drones Corporation) in May 2026. The filing details a fundamental shift from a pharmaceutical genomics company to an AI and quantum computing-focused autonomous vehicle platform developer. While the prose does not fit neatly into the specific event categories (no M\u0026A completion, no earnings release, no executive change, no covenant breach), the material business transformation and strategic repositioning would affect a reasonable investor's assessment of the registrant's operations, market focus, and risk profile.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:14:01.547182+00:00","company_name":"Quantum Cyber N.V.","ticker":"QUCY","filing_date":"2026-05-26"}]}